June 01, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Immunotherapy combination may improve outcomes in unresectable liver cancer
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to results of the randomized phase 3 EMERALD-3 study.Using STRIDE — single-agent tremelimumab (Imjudo, AstraZeneca) and regular-interval durvalumab (Imfinzi, AstraZeneca) — with transarterial
1,548 words~7 min read
